Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc regarding potential securities fraud or unlawful business practices [1] Collaboration Termination - Pfizer decided to return the development and commercialization rights of hemophilia A gene therapy candidate giroctocogene fitelparvovec to Sangamo, despite the therapy being in phase 3 [2] - Sangamo expressed surprise and disappointment at Pfizer's decision to end the collaboration close to anticipated Biologics License Application and Marketing Authorisation Application submissions, expected in early 2025 [3] - The collaboration and license agreement with Pfizer will terminate on April 21, 2025, with Pfizer required to transition the giroctocogene fitelparvovec program back to Sangamo [4] Market Reaction - Sangamo's stock price fell sharply during intraday trading on December 31, 2024 following the announcement of Pfizer's decision [5] About Pomerantz LLP - Pomerantz LLP is a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages awards for class members [6]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

 - Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets -- Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales -TOKYO and RICHMOND, Calif., Dec. 19, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naok ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Senior Vice President, Chief Financial Officer & Principal Accounting Officer Conference Call Participants Gena Wang - Barclays Maury Raycroft - Jefferies Luca Issi - RBC Capital Markets Ri ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this drug developer would post a loss of $0.16 per share when it actually produced a loss of $0.17, delivering a surprise of -6.25%.Over the last four quarter ...

Table of Contents Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2024 FINANCIAL RESULTS th Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years. Pfizer plans to present detailed data from Phase 3 AFFINE t ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been able to make several great advancements regarding its pipeline in the past year. The most notable program advancement would be regarding the fact that the company caught a huge surprise development from the FDA relating to its Fabry Disease treatment program. That is, it was noted by the U.S. agency that it would be able to file a Biologics License Application [BLA] of isaralgagene civaparvovec for the treatment of patients with Fabry Disease [FD] under an A ...

Experience: Former Fund Manager of a Hedge Fund focused on Biotech and Pharmaceutical companies. Over 20 years in the BioPharma Industry, including various roles on the commercial side. Investing Goal: Outperform the XBI each year by identifying and then investing in assets that should change the current standard of care in a particular disease. Portfolio sizing: Typically, high risk/high reward plays will be acquired up to 2 percent positions in my portfolio. More moderate risk/moderate reward positions ma ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena Wang - Barclays Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Lisa Walter - RBC Operator Good afternoon, and we ...